Mission
Revolutionizing Access to Medicines with Multimodal Therapies (MMTs) empowered by AI for Diseases with High Unmet Medical Needs.
About us
Tangramed Biotech is at the forefront of augmented drug polytherapy, combining multiple drugs to target complementary modes of action simultaneously. Our approach integrates novel proprietary AI and experimental tools to address this complexity. Medicines with MMTs rely on both existing and new drugs, representing a modern approach akin to recycling for new alloys.
​​
Tangramed aspires to revolutionize access to medicines with MMTs powered by generative AI, targeting diseases with significant unmet medical needs while ensuring affordability for patients.
-
Tackling diseases with huge unmet needs like Alzheimer’s and glioblastoma.
​
-
Facing exorbitant expenses of new drug development.
​
-
Triumphing over risky clinical trials.
-
Navigating regulations & approvals.
-
Balancing progress and ethics.
-
Ensuring drug access and affordability.
Challenges
Founders
Tangramed's Founders Boast a Proven Track Record in AI,
Backed by Seminal Publications and Granted IP in the Field of
Combinatorial Medicine
